311 top medical experts on Multiple Endocrine Neoplasia Type 2a across 44 countries and 21 U.S. states, including 172 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Multiple Endocrine Neoplasia Type 2a: A form of multiple endocrine neoplasia characterized by the presence of medullary carcinoma (carcinoma, medullary) of the thyroid gland, and usually with the co-occurrence of pheochromocytoma, producing calcitonin and adrenaline, respectively. Less frequently, it can occur with hyperplasia or adenoma of the parathyroid glands. This disease is due to gain-of-function mutations of the MEN2 gene on chromosome 10 (Locus: 10q11.2), also known as the RET proto-oncogene that encodes a receptor protein-tyrosine kinase. It is an autosomal dominant inherited disease.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Multiple Endocrine Neoplasia (574).
  4. Clinical Trials ClinicalTrials.gov : at least 7 including 1 Active, 3 Completed, 2 Recruiting
  5. Synonyms: MEN 2,  MEN 2a,  Multiple Endocrine Type 2a Neoplasia,  Multiple Endocrine Type 2a Neoplasms,  Sipple Syndrome


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Waguespack, Steven G   Pediatric Endocrinology   Google Publications
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas.
    Physician  Highly Cited  Highly Published  Guideline 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments in 2021 from 4 biomedical companies, totalling $9,360, including $9,360 from  Bayer HealthCare Pharmaceuticals Inc.
    Subjects: Thyroid Neoplasms; Carcinoma, Medullary; Proto-Oncogene Proteins c-ret; Carcinoma, Neuroendocrine; Thyroidectomy
    Categories: Genetics; Therapy; Mortality; Surgery; Therapeutic Use; Congenital
    Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. (2015)
    Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. (2017)

  2. Gagel, Robert F   Endocrinology, Diabetes & Metabolism  Google Publications
    Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030.
    Physician  Highly Cited  Highly Published  Guideline 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Subjects: Thyroid Neoplasms; Proto-Oncogene Proteins c-ret; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Adrenal Gland Neoplasms
    Categories: Genetics; Mortality; Therapy; Congenital; Methods; Diagnosis
    Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. (2015)
    Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. (2017)

  3. Evans, Douglas B   Surgical Oncology  Google Publications
    Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.
    Physician  Highly Cited  Highly Published  Guideline 
    Subjects: Thyroid Neoplasms; Carcinoma, Medullary; Thyroidectomy; Antineoplastic Combined Chemotherapy Protocols; Calcitonin
    Categories: Surgery; Therapy; Diagnosis; Methods; Blood; Congenital
    Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. (2015)
    Do the recent American Thyroid Association (ATA) Guidelines accurately guide the timing of prophylactic thyroidectomy in MEN2A? (2010)

  4. Asa, Sylvia L   Anatomic Pathology  Google Publications
    Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, 44106, USA. Top Hospital
    Physician  Guideline 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 88/100
    Disclosed payments in 2021 from 4 biomedical companies, totalling $1,312.5, including $1,312.5 from  LEICA MICROSYSTEMS INC.
    Subjects: Thyroid Neoplasms; Adenocarcinoma, Follicular; Carcinoma, Medullary; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine
    Categories: Genetics; Pathology; Therapy; Congenital; Methods; Therapeutic Use
    Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. (2015)
    Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates. (2021)

  5. Grubbs, Elizabeth G   Surgical Oncology   Google Publications
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT 17.6000, Houston, TX 77030, USA.
    Physician  Highly Published  Case Reports 
    Medical school: Duke University School of Medicine (MD, 1999)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Subjects: Thyroid Neoplasms; Proto-Oncogene Proteins c-ret; Multiple Endocrine Neoplasia Type 1; Carcinoma, Medullary; Thyroidectomy
    Categories: Genetics; Psychology; Surgery; Diagnosis; Methods; Blood
    Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. (2017)
    Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. (2014)

  6. Perrier, Nancy D   Surgical Oncology  Google Publications
    Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030.
    Physician  Highly Published 
    Medical school: Louisiana State University School of Medicine In New Orleans (MD, 1993)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Subjects: Thyroid Neoplasms; Carcinoma, Medullary; Proto-Oncogene Proteins c-ret; Adenomatous Polyposis Coli; Calcitonin
    Categories: Genetics; Psychology; Surgery; Therapy; Diagnosis; Blood
    Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. (2017)
    Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. (2011)

  7. Widemann, Brigitte C   Pediatric Hematology-Oncology  ClinicalTrials.gov Google Publications
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Clinical Center, National Institutes of Health, Bethesda, Maryland, DC, USA.
    Physician  Case Reports 
    Subjects: Adrenocortical Carcinoma; Carcinoma, Medullary; Colorectal Neoplasms, Hereditary Nonpolyposis; MutS Homolog 2 Protein; Piperidines
    Categories: Genetics; Drug Therapy; Therapeutic Use; Congenital
    Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. (2018)
    Case report of adrenocortical carcinoma associated with double germline mutations in MSH2 and RET. (2021)

  8. Lodish, Maya   Pediatric Endocrinology  Google Publications
    Developmental Endocrine Oncology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development NICHD, Bethesda, Maryland.
    Physician 
    Subjects: Carcinoma, Medullary; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms
    Categories: Drug Therapy; Genetics; Therapeutic Use; Congenital
    Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. (2018)
    Multiple endocrine neoplasia type 2. (2013)

  9. Baloch, Zubair W   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA. Top Hospital
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 78/100
    Subjects: Carcinoma, Medullary; Thyroid Neoplasms; Carcinoma, Neuroendocrine; Cell Proliferation; High-Throughput Nucleotide Sequencing
    Categories: Genetics; Pathology; Congenital; Methods
    Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience. (2016)
    C-Cells and their Associated Lesions and Conditions: A Pathologists Perspective. (2015)

  10. Schlumberger, Martin    Google Publications
    Gustave Roussy, Laboratoire de Pathologie Expérimentale, F-94800 Villejuif, France.
    Physician  Highly Cited  Highly Published  Guideline 
    Subjects: Carcinoma, Medullary; Proto-Oncogene Proteins c-ret; Thyroid Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine
    Categories: Genetics; Therapy; Congenital; Methods; Pathology; Therapeutic Use
    Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. (2015)
    Medullary thyroid carcinoma. (2010)

  11. Chen, Herbert   Surgery  Google Publications
    Endocrine Surgery Research Laboratory, The University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
    Physician  Highly Published 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72.3/100
    Subjects: Thyroid Neoplasms; Carcinoma, Medullary; Thyroidectomy; Cell Cycle; Cyclin-Dependent Kinase 5
    Categories: Genetics; Congenital; Metabolism; Pathology; Surgery
    Current understanding and management of medullary thyroid cancer. (2013)
    Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis. (2015)

  12. Glod, John W   Pediatric Hematology-Oncology   Google Publications
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Clinical Center, National Institutes of Health, Bethesda, Maryland, DC, USA.
    Physician  Highly Published  Case Reports 
    Subjects: Thyroid Neoplasms; Carcinoma, Neuroendocrine; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines
    Categories: Drug Therapy; Genetics; Therapeutic Use; Therapy; Antagonists & Inhibitors; Complications
    Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. (2018)
    Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2. (2020)

  13. Graham, Paul H   Surgical Oncology  Google Publications
    Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030.
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Subjects: Thyroid Neoplasms; Proto-Oncogene Proteins c-ret; Carcinoma, Medullary; Carcinoma, Neuroendocrine
    Categories: Genetics; Congenital; Pathology
    Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. (2017)
    All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. (2017)

  14. Hu, Mimi I   Endocrinology, Diabetes & Metabolism  Google Publications
    Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA.
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Subjects: Thyroid Neoplasms; Proto-Oncogene Proteins c-ret; Adrenal Gland Neoplasms; Carcinoma, Medullary; Pheochromocytoma
    Categories: Genetics; Mortality; Congenital; Pathology
    The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. (2013)
    All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. (2017)

  15. Kebebew, Electron   Surgery   Google Publications
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Stanford University, School of Medicine, Stanford, California. Electronic address: . Top Hospital
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 65/100
    Subjects: Carcinoma, Medullary; Thyroid Cancer, Papillary; Thyroid Neoplasms
    Categories: Pathology; Congenital; Diagnosis; Drug Therapy
    Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment. (2019)
    Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. (2014)

  16. Lee, Jeffrey E   Surgical Oncology  Google Publications
    Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030.
    Physician  Highly Published 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Subjects: Thyroid Neoplasms; Proto-Oncogene Proteins c-ret; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Societies, Medical
    Categories: Genetics; Surgery; Congenital; Methods; Pathology; Standards
    Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. (2017)
    Do the recent American Thyroid Association (ATA) Guidelines accurately guide the timing of prophylactic thyroidectomy in MEN2A? (2010)

  17. Morris, John C   Endocrinology, Diabetes & Metabolism  Google Publications
    4 Division of Endocrinology, Department of Medicine, Mayo Clinic , Rochester, Minnesota. Top Hospital
    Physician  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Subjects: Adrenal Gland Neoplasms; Pheochromocytoma; Proto-Oncogene Proteins c-ret; Thyroid Neoplasms; Carcinoma, Medullary
    Categories: Genetics
    Multiple endocrine neoplasia type 2A due to an exon 8 (G533C) mutation in a large North American kindred. (2013)
    Clinical Features of a Family with Multiple Endocrine Neoplasia Type 2A Caused by the D631Y RET Mutation. (2017)

  18. Lee, Nancy   Radiation Oncology  Google Publications
    Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
    Physician  Guideline 
    Disclosed payments in 2021 from 4 biomedical companies, totalling $8,678.69, including $4,620 from  F. Hoffmann-La Roche AG
    Subjects: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Radiotherapy; Thyroid Neoplasms
    Categories: Therapy; Congenital; Methods; Therapeutic Use
    Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. (2015)

  19. Jimenez, Camilo   Internal Medicine  Google Publications
    Physician 
    Medical school: Other (MD, 1995)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments from biomedical company (Merck Sharp & Dohme Corporation) in 2021 for $937.5
    Subjects: Thyroid Neoplasms; Adrenal Gland Neoplasms; Carcinoma, Medullary; Pheochromocytoma; Proto-Oncogene Proteins c-ret
    Categories: Mortality; Therapy; Genetics
    Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. (2011)
    The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. (2013)

  20. Sippel, Rebecca S   Surgery  Google Publications
    Physician 
    Medical school: Washington University School of Medicine (MD, 1999)
    Medicare Accepted
    Subjects: Thyroid Neoplasms; Carcinoma, Medullary; Thyroidectomy; Proto-Oncogene Proteins c-ret
    Categories: Genetics; Congenital; Pathology; Surgery
    Current understanding and management of medullary thyroid cancer. (2013)
    Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival. (2013)

Note:
  1. These experts have limited publications on this topic in our database, so expertise assessment may not be accurate.
  2. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);